TY  - JOUR
AU  - Guagliardo, Roberta
AU  - Merckx, Pieterjan
AU  - Zamborlin, Agata
AU  - Backer, Lynn de
AU  - Echaide Torreguitar, Mercedes
AU  - Pérez-Gil, Jesús
AU  - Smedt, Stefaan C. de
AU  - Raemdonck, Koen
PY  - 2019
DO  - 10.3390/pharmaceutics11090431
SN  - 1999-4923, ESSN: 1999-4923
UR  - https://hdl.handle.net/20.500.14352/13473
T2  - Pharmaceutics
AB  - Two decades since the discovery of the RNA interference (RNAi) pathway, we are now witnessing the approval of the first RNAi-based treatments with small interfering RNA (siRNA) drugs. Nevertheless, the widespread use of siRNA is limited by various...
LA  - eng
M2  - 1
PB  - MDPI
KW  - siRNA delivery
KW  - Nanoparticles
KW  - Pulmonary surfactant
TI  - Nanocarrier lipid composition modulates the impact of pulmonary surfactant protein B (SP-B) on cellular delivery of siRNA
TY  - journal article
VL  - 11
ER  -